Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes

Emerging Infectious Diseases

Volumn 22, Issue 10, 2016, Pages 1732-1740

  Mesher, David ^a,b   Soldan, Kate ^a   Lehtinen, Matti ^c   Beddows, Simon ^a   Brisson, Marc ^d,e,f   Brotherton, Julia M L ^g,h   Chow, Eric P F ^i,j   Cummings, Teresa ^k   Drolet, Mélanie ^e,f   Fairley, Christopher K ^i,j   Garland, Suzanne M ^h,l,m   Kahn, Jessica A ^n,o   Kavanagh, Kimberley ^p   Markowitz, Lauri ^q   Pollock, Kevin G ^r   Söderlund Strand, Anna ^s   Sonnenberg, Pam ^t   Tabrizi, Sepehr N ^h,l,m   Tanton, Clare ^t   Unger, Elizabeth ^q   Thomas, Sara L ^b   more..

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e University Laval   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g VICTORIAN CYTOLOGY SERVICE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^j MONASH UNIVERSITY   (Australia)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^m ROYAL WOMEN'S HOSPITAL   (Australia)

ⁿ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^o UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^p UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r HEALTH PROTECTION SCOTLAND   (United Kingdom)

^s Clinical Immunology and Transfusion Medicine   (Sweden)

^t UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE; ARTICLE; DATA ANALYSIS; DATA EXTRACTION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; META ANALYSIS; NONHUMAN; NONVACCINE GENOTYPE; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; QUALITY CONTROL; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VACCINATION; ADOLESCENT; CROSS PROTECTION; FEMALE; GENETICS; IMMUNOLOGY; PAPILLOMAVIRIDAE; PREVALENCE; PREVENTIVE HEALTH SERVICE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; CROSS PROTECTION; FEMALE; GENOTYPE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84988530527     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2210.160675     Document Type: Article

References (39)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. http://dx.doi.org/10.1016/S1470-2045(10)70230-8
3. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927–35. http://dx.doi.org/10.1002/ijc.25396
4. Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, et al. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J Clin Pathol. 2015;68:135–40. http://dx.doi.org/10.1136/jclinpath-2014-202681
5. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–8. http://dx.doi.org/10.1016/S0140-6736(07)60852-6
6. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.
7. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al.; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23. http://dx.doi.org/10.1056/NEJMoa1405044
8. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199:926–35. http://dx.doi.org/10.1086/597307
9. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–10.
10. Cervical Cancer Action. Global maps. Global progress in HPV vaccination. 2014 Sep [cited 2016 Apr 22]. http://www.cervicalcanceraction.org/comments/comments3.php
11. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–80. http://dx.doi.org/10.1016/S1473-3099(14)71073-4
12. Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, et al. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer. 2012;131:2832–8. http://dx.doi.org/10.1002/ijc.27586
13. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–9. http://dx.doi.org/10.1016/S1473-3099(12)70187-1
14. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens— part B: biological agents. Lancet Oncol. 2009;10:321–2. http://dx.doi.org/10.1016/S1470-2045(09)70096-8
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. http://dx.doi.org/10.1371/journal.pmed.1000100
16. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6:e009915. http://dx.doi.org/10.1136/bmjopen-2015-009915
17. Söderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev. 2014;23:2757–64. http://dx.doi.org/10.1158/1055-9965.EPI-14-0687
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. http://dx.doi.org/10.1136/bmj.327.7414.557
19. Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol. 2011;83:1744–51. http://dx.doi.org/10.1002/jmv.22167
20. Dunne EF, Naleway A, Smith N, Crane B, Weinmann S, Braxton J, et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012–2013. J Infect Dis. 2015;212:1970–5. http://dx.doi.org/10.1093/infdis/jiv342
21. Cummings T, Zimet GD, Brown D, Tu W, Yang Z, Fortenberry JD, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine. 2012;30:5496–9. http://dx.doi.org/10.1016/j.vaccine.2012.06.057
22. Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130:e249–56. http://dx.doi.org/10.1542/peds.2011-3587
23. Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013;382:1795–806. http://dx.doi.org/10.1016/S0140-6736(13)61947-9
24. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–66. http://dx.doi.org/10.1016/S1473-3099(14)70841-2
25. Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis. 2016;22:56–64. http://dx.doi.org/10.3201/eid2201.150736
26. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968. http://dx.doi.org/10.1542/peds.2015-1968
27. Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis. 2015;15:1314–23. http://dx.doi.org/10.1016/S1473-3099(15)00055-9
28. Public Health England. Sexually transmitted infections (STIs): annual data tables. 2015 Jun 23 [cited 2016 Apr 22]. https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables
29. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. http://dx.doi.org/10.1136/bmj.f2032
30. Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91:214–9. http://dx.doi.org/10.1136/sextrans-2014-051813
31. Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208:1397–403. http://dx.doi.org/10.1093/infdis/jit361
32. Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer. 2006;119:2612–9. http://dx.doi.org/10.1002/ijc.22131
33. Laukkanen P, Koskela P, Pukkala E, Dillner J, Läärä E, Knekt P, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol. 2003;84:2105–9. http://dx.doi.org/10.1099/vir.0.18995-0
34. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789–99. http://dx.doi.org/10.1086/657321
35. Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Koushik A, et al. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. Cancer Epidemiol Biomarkers Prev. 2015;24:286–90. http://dx.doi.org/10.1158/1055-9965.EPI-14-0566
36. Cornall AM, Phillips S, Cummins E, Garland SM, Tabrizi SN. In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies. J Virol Methods. 2015;214:10–4. http://dx.doi.org/10.1016/j.jviromet.2014.12.007
37. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 [cited 2016 Apr 22]. http://handbook.cochrane.org/
38. Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178:625–34. http://dx.doi.org/10.1093/aje/kwt018
39. Safaeian M, Rodriguez AC. Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol. 2014;180:1076–81. http://dx.doi.org/10.1093/aje/kwu265